Velan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save Progenics

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today released a detailed presentation on Progenics. The presentation outlines the Company’s persistent underperformance and strategic failures and provides our Nominees’ comprehensive strategic plan to address key performance pitfalls, years of neglecting stockholders’ interests and egregious governance issues at the Company.